<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882319</url>
  </required_header>
  <id_info>
    <org_study_id>HP-5000-US-06</org_study_id>
    <nct_id>NCT04882319</nct_id>
  </id_info>
  <brief_title>Irritation and Sensitization Study of HP-5000 Topical System</brief_title>
  <official_title>An Evaluator-blinded, Randomized Within-subject Repeat Insult Study to Evaluate Potential Skin Irritation and Sensitization of HP-5000 (Diclofenac Sodium Topical System) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess skin irritation and sensitization for HP-5000 patch in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an evaluator-blinded, randomized phase 1 study evaluating skin irritation and&#xD;
      sensitization of HP-5000 topical system in comparison to control patches. The study will&#xD;
      consist of a 4-week Screening Phase and a Treatment Phase. The Treatment Phase will consist&#xD;
      of the following periods: an Induction Period, a Rest Period followed by a Challenge Period&#xD;
      and if needed, a Re-Challenge Period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating skin irritation with Mean Irritation Score (MIS)</measure>
    <time_frame>21 days</time_frame>
    <description>To evaluate skin irritation after exposure to HP-5000, placebo and saline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating skin sensitization with the number and proportion of subjects sensitized using descriptive statistics</measure>
    <time_frame>21 days</time_frame>
    <description>To evaluate skin sensitization after exposure to HP-5000, placebo and saline.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>HP-5000 Topical Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HP-5000, placebo and saline will be administered simultaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HP-5000 Topical Patch</intervention_name>
    <description>HP-5000, placebo and saline will be administered simultaneously</description>
    <arm_group_label>HP-5000 Topical Patch</arm_group_label>
    <other_name>HP-5000 Patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HP-5000 Placebo Patch</intervention_name>
    <description>HP-5000, placebo and saline will be administered simultaneously</description>
    <arm_group_label>HP-5000 Topical Patch</arm_group_label>
    <other_name>Placebo Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Patch</intervention_name>
    <description>HP-5000, placebo and saline will be administered simultaneously</description>
    <arm_group_label>HP-5000 Topical Patch</arm_group_label>
    <other_name>Saline Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject provides written informed consent prior to entering the study or undergoing&#xD;
             any study procedures;&#xD;
&#xD;
          -  Subject is a generally healthy male or female 18 to 65 years of age;&#xD;
&#xD;
          -  Subject is considered to be healthy on the basis of medical history, physical&#xD;
             examination, vital signs, normal electrocardiogram (ECG) and clinical laboratory test&#xD;
             results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant or lactating, or females planning a pregnancy during the course of&#xD;
             the trial;&#xD;
&#xD;
          -  Subject has severe cardiac, renal or hepatic impairment;&#xD;
&#xD;
          -  Subject has used any topical drugs at the patch application site within 72 hours prior&#xD;
             to dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Noven Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>(305) 253-5099</phone>
    <email>ClinicalTrials@noven.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TKL Research</name>
      <address>
        <city>Fair Lawn</city>
        <state>New Jersey</state>
        <zip>07410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

